Alexandria Phan, MD, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic GEP-NETs.
Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses the importance of the approval of lanreotide for unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More